PGP and cancer: However, low-dose TCZ afforded markedly low P-gp inhibitory activity, with less than a 200% increase, thereby indicating that P-gp inhibition may fail to play a major role in sensitizing P-gp-overexpressing-resistant cancer cells to VIC.